DermTech, Inc., the global leader in non-invasive molecular dermatology, has collaborated with two multi-national pharmaceutical companies. These two recent collaborations are further examples of the company's value added proposition and leadership in molecular dermatology.

The company intends to focus on offering the newest gene expression technology to enhance the understanding of treatment effects and response rates in target populations with new drugs and treatments, providing an invaluable tool in biopharmaceutical drug development.

DermTech is the global leader in molecular dermatology. It markets and develops non-invasive gene expression tests to aid the clinical diagnosis of skin cancer, assess inflammatory diseases, and to personalize drug treatment. DermTech's technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. The mission is to transform dermatology by delivering highly accurate, objective information to physicians to improve care and reduce costs.